Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

Leukemia·2017

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Leukemia·2016

Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging.

Journal of thrombosis and haemostasis : JTH·2014

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).

Leukemia·2014

Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Blood cancer journal·2013

Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms.

Leukemia·2026

Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.

Leukemia·2026

KLF4/MLL3 complex axis drives NRBP2 transcription to eliminate acute myeloid leukemia cells.

Leukemia·2026

Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

Leukemia·2026

Incidence, prevalence, and survival outcomes of patients with myeloproliferative neoplasms in the United States: a Surveillance, Epidemiology, and End Results (SEER) database analysis, years 2000-2021.

Leukemia·2026

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.

Leukemia·2026

Deficiency of GLUT1 in macrophages reprograms tumor-associated macrophages to normalize tumor vasculature and retards the progression of tumors.

International journal of biological sciences·2026

A proposal of good manufacturing practices (GMP) laboratory for CAR T-cell therapy in Latin America and the Caribbean: challenges and opportunities.

Frontiers in public health·2026

In vivo selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft model.

NAR cancer·2026

From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma.

Frontiers in immunology·2026

Doravirine and islatravir for HIV-1 treatment: A systematic review and meta-analysis with GRADE assessment.

Therapeutic advances in infectious disease·2026

Advancement in Inflammation-responsive Drug Delivery System for Chronic Inflammation.

Anti-inflammatory & anti-allergy agents in medicinal chemistry·2026

Related Experiment Videos

Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera

Related Concept Videos

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging.

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).

Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms.

Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.

KLF4/MLL3 complex axis drives NRBP2 transcription to eliminate acute myeloid leukemia cells.

Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

Incidence, prevalence, and survival outcomes of patients with myeloproliferative neoplasms in the United States: a Surveillance, Epidemiology, and End Results (SEER) database analysis, years 2000-2021.

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.

Deficiency of GLUT1 in macrophages reprograms tumor-associated macrophages to normalize tumor vasculature and retards the progression of tumors.

A proposal of good manufacturing practices (GMP) laboratory for CAR T-cell therapy in Latin America and the Caribbean: challenges and opportunities.

In vivo selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft model.

From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma.

Doravirine and islatravir for HIV-1 treatment: A systematic review and meta-analysis with GRADE assessment.

Advancement in Inflammation-responsive Drug Delivery System for Chronic Inflammation.

Related Experiment Videos

Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera

Related Concept Videos

Related Articles